The DOI matches its Crossref record; 289 of the 289 references it cites were found in a registry or an index.
Ten years of anti-vascular endothelial growth factor therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–289 of 289
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319
Flk-1 as a target for tumor growth inhibition.
Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Longhi, M. P., Hui, T. H., Tang, C., Levitzki, A., Gazit, A., et al. (1996) · PubMed · Cited by 316
Orlandini, M., Marconcini, L., Ferruzzi, R., & Oliviero, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11675 · Cited by 315
Fc RECEPTORS AND THEIR INTERACTIONS WITH IMMUNOGLOBULINS
Raghavan, M., & Bjorkman, P. J. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.181 · Cited by 314
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
Self-citationKim, K. J., Li, B., Houck, K., Winer, J., & Ferrara, N. (1992) · Growth Factors · doi:10.3109/08977199209023937 · Cited by 306
Self-citationBiomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 295
Sandmann, T., Bourgon, R., Garcia, J., Li, C., Cloughesy, T., Chinot, O. L., Wick, W., Nishikawa, R., Mason, W., Henriksson, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5005 · Cited by 293
Pajusola, K., Aprelikova, O. N., Korhonen, J., Kaipainen, A., Pertovaara, L., Alitalo, R., & Alitalo, K. K. (1992) · PubMed · Cited by 285
Human Vascular Permeability Factor
Connolly, D. T., Olander, J. V., Heuvelman, D., Nelson, R., Monsell, R., Siegel, N., Haymore, B. L., Leimgruber, R., & Feder, J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47212-8 · Cited by 284
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
Finke, J., Ko, J., Rini, B., Rayman, P., Ireland, J., & Cohen, P. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.030 · Cited by 281
Vascular endothelial grouth facter B, a novel growth facter for endothelial cells
Olffson, B. (1996) · Medical Entomology and Zoology · Cited by 279
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Bergh, J., Bondarenko, I. M., Lichinitser, M. R., Liljegren, A., Greil, R., Voytko, N. L., Makhson, A. N., Cortes, J., Lortholary, A., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7376 · Cited by 264
Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., & de Vos, A. M. (1998) · Structure · doi:10.1016/s0969-2126(98)00116-6 · Cited by 264
Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma
Snuderl, M., Batista, A., Kirkpatrick, N. D., Ruiz de Almodovar, C., Riedemann, L., Walsh, E. C., Anolik, R., Huang, Y., Martin, J. D., Kamoun, W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.036 · Cited by 251
Self-citationGerber, H., Kowalski, J., Sherman, D. A., Eberhard, D. A., & Ferrara, N. (2000) · PubMed · Cited by 251
Self-citationFerrara, N. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-07-0590 · Cited by 251
Self-citationRole of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Ferrara, N., Mass, R. D., Campa, C., & Kim, R. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145635 · Cited by 238
Self-citationAnti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd
Sun, Z., Li, X., Massena, S., Kutschera, S., Padhan, N., Gualandi, L., Sundvold-Gjerstad, V., Gustafsson, K., Choy, W. W., Zang, G., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111343 · Cited by 237
Programmed Translational Readthrough Generates Antiangiogenic VEGF-Ax
Eswarappa, S. M., Potdar, A. A., Koch, W. J., Fan, Y., Vasu, K., Lindner, D., Willard, B., Graham, L. M., DiCorleto, P. E., & Fox, P. L. (2014) · Cell · doi:10.1016/j.cell.2014.04.033 · Cited by 236
Ide, A. (1939) · American Journal of Roentgenology · Cited by 234
Dellian, M., Witwer, B. P., Salehi, H. A., Yuan, F., & Jain, R. K. (1996) · Europe PMC (PubMed Central) · Cited by 232
Holz, F. G., Roider, J., Ogura, Y., Korobelnik, J.-F., Simader, C., Groetzbach, G., Vitti, R., Berliner, A. J., Hiemeyer, F., Beckmann, K., et al. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-301504 · Cited by 228
de Groot, J. F., Lamborn, K. R., Chang, S. M., Gilbert, M. R., Cloughesy, T. F., Aldape, K., Yao, J., Jackson, E. F., Lieberman, F., Robins, H. I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1636 · Cited by 228
Tyrphostins and Other Tyrosine Kinase Inhibitors
Levitzki, A., & Mishani, E. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142657 · Cited by 226
Schwesinger, C., Yee, C., Rohan, R. M., Joussen, A. M., Fernandez, A., Meyer, T. N., Poulaki, V., Ma, J. J. K., Redmond, T. M., Liu, S., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64063-1 · Cited by 225
Self-citationROSENFELD, P., SCHWARTZ, S., BLUMENKRANZ, M., MILLER, J., HALLER, J., REIMANN, J., GREENE, W., & SHAMS, N. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.01.043 · Cited by 223
Schmoll, H.-J., Cunningham, D., Sobrero, A., Karapetis, C. S., Rougier, P., Koski, S. L., Kocakova, I., Bondarenko, I., Bodoky, G., Mainwaring, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5355 · Cited by 213
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Lopa, S. H., & Wolmark, N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4711 · Cited by 209
Ferrara, N. (2010) · Nature Medicine · doi:10.1038/nm1010-1107 · Cited by 203
Self-citationMcTigue, M. A., Wickersham, J. A., Pinko, C., Showalter, R. E., Parast, C. V., Tempczyk-Russell, A., Gehring, M. R., Mroczkowski, B., Kan, C.-C., Villafranca, J. E., et al. (1999) · Structure · doi:10.1016/s0969-2126(99)80042-2 · Cited by 203
Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody
Ryan, A. M., Eppler, D. B., Hagler, K. E., Bruner, R. H., Thomford, P. J., Hall, R. L., Shopp, G. M., & O'Neill, C. A. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700115 · Cited by 202
Davis-Smyth, T., Chen, H., Park, J., Presta, L. G., & Ferrara, N. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00872.x · Cited by 200
Self-citationPreclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment
Strumberg, D. (2005) · Drugs of Today · doi:10.1358/dot.2005.41.12.937959 · Cited by 195
Hegde, P. S., Jubb, A. M., Chen, D., Li, N. F., Meng, Y. G., Bernaards, C., Elliott, R., Scherer, S. J., & Chen, D. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2535 · Cited by 193
Ramlau, R., Gorbunova, V., Ciuleanu, T. E., Novello, S., Ozguroglu, M., Goksel, T., Baldotto, C., Bennouna, J., Shepherd, F. A., Le-Guennec, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6932 · Cited by 188
Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance
Levitzki, A. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140341 · Cited by 186
Improved Vision-Related Function after Ranibizumab for Macular Edema after Retinal Vein Occlusion
Varma, R., Bressler, N. M., Suñer, I., Lee, P., Dolan, C. M., Ward, J., Colman, S., & Rubio, R. G. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.05.017 · Cited by 166
Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P., Czito, B. G., Lin, P.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161
PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Bais, C., Wu, X., Yao, J. J., Yang, S., Crawford, Y., McCutcheon, K. M., Tan, C., Kolumam, G. A., Vernes, J.-M., Eastham‐Anderson, J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.033 · Cited by 159
Self-citationBurden of illness of diabetic macular edema: literature review
Chen, E., Looman, M., Laouri, M., Gallagher, M., Van Nuys, K., Lakdawalla, D., & Fortuny, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.482503 · Cited by 158
Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B., & Sirzén, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2794 · Cited by 158
Antibody Humanization Using Monovalent Phage Display
Baca, M., Presta, L. G., O'Connor, S. J., & Wells, J. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10678 · Cited by 147
Little, H. L. (1956) · PubMed · Cited by 140
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
VANDER, J. F. (2012) · Yearbook of Ophthalmology · doi:10.1016/j.yoph.2011.12.002 · Cited by 138
血小板由来増殖因子/血管内皮増殖因子ファミリーと相関するc‐fos誘導性遺伝子の同定
Orlandini, M., Marconcini, L., Ferruzzi, R., & Oliviero, S. (1996) · Cited by 138
Carrato, A., Świeboda-Sadlej, A., Staszewska-Skurczyńska, M., Lim, R. S. C., Roman, L., Shparyk, Y. V., Bondarenko, I., Jonker, D. J., Sun, Y. P., Cruz-Vargas, J. A. D. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1930 · Cited by 137
Hanrahan, E. O., Lin, H. Y., Kim, E. S., Yan, S., Du, D. Z., McKee, K. S., Tran, H. T., Lee, J. J., Ryan, A. J., Langmuir, P. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4279 · Cited by 134
Pathobiology of Ocular Disease
Blodi, F. C. (1983) · Archives of Ophthalmology · doi:10.1001/archopht.1983.01040010144037 · Cited by 129
Liang, W., Dennis, M. S., Stawicki, S. S., Chanthery, Y. H., Pan, Q., Chen, Y., Eigenbrot, C. W., Yin, J., Koch, A., Wu, X., et al. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.021 · Cited by 127
Self-citationShima, D. T., Gougos, A., Miller, J. W., Tolentino, M. J., ROBINSON, G. C., Adamis, A. P., & D'Amore, P. A. (1996) · PubMed · Cited by 126
Self-citationAbedi, F., Wickremasinghe, S., Islam, A. F. M., Inglis, K. M., & Guymer, R. H. (2014) · Retina · doi:10.1097/iae.0000000000000134 · Cited by 126
Bressler, N. M., Doan, Q. V., Varma, R., Lee, P. P., Suñer, I. J., Dolan, C., Danese, M. D., Yu, E., Tran, I., & Colman, S. S. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.140 · Cited by 123
Robert, N. J., Saleh, M. N., Paul, D., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.005 · Cited by 119
Aiello, L. P., Beck, R. W., Bressler, N. M., Browning, D. J., Chalam, K. V., Davis, M. D., Ferris, F. L., Glassman, A. R., Maturi, R. K., Stockdale, C. R., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.09.058 · Cited by 116
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
Singh, M., & Ferrara, N. (2012) · Nature Biotechnology · doi:10.1038/nbt.2286 · Cited by 114
Self-citationRosenberg, C. L., Motokura, T., Kronenberg, H. M., & Arnold, A. (1993) · PubMed · Cited by 107
Yao, J. J., Wu, X., Zhuang, G., Kasman, I. M., Vogt, T., Phan, V. T., Shibuya, M., Ferrara, N., & Bais, C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109029108 · Cited by 102
Self-citationKrupitskaya, Y., & Wakelee, H. A. (2009) · PubMed · Cited by 98
Ophthalmic timolol: Plasma concentration and systemic cardiopulmonary effects
Nieminen, T. V. M., Lehtimäki, T. J., Mäenpää, J., Ropo, A., Uusitalo, H. M. T., & Kähönen, M. A. P. (2006) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510601034736 · Cited by 95
Therapies directed at vascular endothelial growth factor
Manley, P. W., Martiny‐Baron, G., Schlaeppi, J.-M., & Wood, J. M. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1715 · Cited by 92
Chung, A. S., Kowanetz, M., Wu, X., Zhuang, G., Ngu, H., Finkle, D., Kömüves, L. G., Peale, F. V., Jr., & Ferrara, N. (2012) · The Journal of Pathology · doi:10.1002/path.4052 · Cited by 88
Self-citationObservations on the Choroidal Circulation
Ashton, N. (1952) · British Journal of Ophthalmology · doi:10.1136/bjo.36.9.465 · Cited by 87
Future of Monoclonal Antibodies in the Treatment of Hematologic Malignancies
Reff, M. E., Hariharan, K., & Braslawsky, G. R. (2002) · Cancer Control · doi:10.1177/107327480200900207 · Cited by 83
Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Singh, M., Couto, S. S., Forrest, W. F., Lima, A., Cheng, J. H., Molina, R., Long, J. E., Hamilton, P., McNutt, A., Kasman, I. M., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4053 · Cited by 75
Self-citationPazopanib versus Sunitinib in Renal Cancer
Motzer, R. J., McCann, L., & Deen, K. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1311795 · Cited by 65
Brauer, M. J., Zhuang, G., Schmidt, M., Yao, J. J., Wu, X., Kaminker, J. S., Jurinka, S. S., Kolumam, G. A., Chung, A. S., Jubb, A. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3635 · Cited by 64
Self-citationVision-Related Function after Ranibizumab Treatment for Diabetic Macular Edema
Bressler, N. M., Varma, R., Suñer, I. J., Dolan, C., Ward, J., Ehrlich, J. S., Colman, S. S., & Turpcu, A. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.008 · Cited by 60
Pathobiology of Ocular Disease
Katz, B. (1995) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-199506000-00016 · Cited by 53
de Haas, S., Delmar, P., Bansal, A. T., Moisse, M., Miles, D. W., Leighl, N. B., Escudier, B. J., Cutsem, E. V., Carmeliet, P., Scherer, S. J., et al. (2014) · Angiogenesis · doi:10.1007/s10456-014-9438-1 · Cited by 51
Frennesson, C. I., Nilsson, U., Peebo, B. B., & Nilsson, S. E. G. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01576.x · Cited by 49
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells
Miki, A., Miki, K., Ueno, S., Wersinger, D. M. B., Berlinicke, C., Shaw, G. C., Usui, S., Wang, Y., Zack, D. J., & Campochiaro, P. A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22129 · Cited by 47
Lassen, U., Chinot, O. L., McBain, C. A., Mau‐Sørensen, M., Larsen, V. A., Barrié, M., Roth, P., Krieter, O., Wang, K., Habben, K., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov019 · Cited by 45
Current phase 1/2 research for neovascular age-related macular degeneration
Pecen, P. E., & Kaiser, P. K. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000147 · Cited by 43
Borooah, S., Jeganathan, V. S. E., Armbrecht, A. M., Oladiwura, D., Gavin, M., Dhillon, B., & Cackett, P. (2015) · Eye · doi:10.1038/eye.2015.83 · Cited by 42
Bill, R., Fagiani, E., Zumsteg, A., Antoniadis, H., Johansson, D., Haefliger, S., Albrecht, I., Hilberg, F., & Christofori, G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3036 · Cited by 42
Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
Blagoev, K. B., Wilkerson, J., Stein, W. D., Motzer, R. J., Bates, S. E., & Fojo, A. T. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.015 · Cited by 42
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy
Johnson, L., Huseni, M. A., Smyczek, T., Lima, A., Yeung, S., Cheng, J. H., Molina, R., Kan, D., Mazière, A. M. G. L. D., Klumperman, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67892 · Cited by 40
Hodge, W., Lalonde, R., Sampalis, J. S., & Deschênes, J. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.2.393 · Cited by 38
Tang, P. A., & Moore, M. J. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13502637 · Cited by 37
The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer
Secord, A. A., Nixon, A. B., & Hurwitz, H. I. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.08.033 · Cited by 28
An update on clinical trials of targeted therapies in thyroid cancer
Haraldsdóttir, S., & Shah, M. H. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000029 · Cited by 27
Ziv-aflibercept: binding to more than VEGF-A—does more matter?
Clarke, J. M., & Hurwitz, H. I. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.197 · Cited by 26
Boyer, D. S. (2009) · Investigative Ophthalmology & Visual Science · Cited by 22
Boyer, D. S. (2013) · Investigative Ophthalmology & Visual Science · Cited by 14
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Self-citationAptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Metadata
- Authors
- Ferrara, N., & Adamis, A. P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2016-01-18
- Volume
- 15
- Issue
- 6
- Pages
- 385-403
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2293809486
- Cited by
- 1,030
- References
- 289
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.